カテゴリー： QYResearch, 世界, 医療/バイオ

注射用ヒアルロン酸＆ボツリヌス毒素のグローバル市場2023年：注射用ヒアルロン酸、ボツリヌス毒素

◆英語タイトル：Global Injectable Hyaluronic Acid and Botulinum Toxin Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA8796）◆商品コード：QYR23MA8796
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：112
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の注射用ヒアルロン酸＆ボツリヌス毒素市場について調査・分析し、世界の注射用ヒアルロン酸＆ボツリヌス毒素市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（注射用ヒアルロン酸、ボツリヌス毒素）、用途別セグメント分析（化粧品、医療）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、AbbVie、Galderma、LG Life Sciences、Merz、Medytox、Hugel、Croma-Pharma、Beijing IMEIK、Bloomage Bio、Elravie (Humedix)、Cleviel (Pharma Research Products)、Haohai Biological、Teoxane、Sinclair、Suneva Medical、CG Bio、SciVision Biotech、Prollenium、Bohus BioTech、Caregen、Ipsen、LIBP、US World Meds、Daewoong、JETEMAなどが含まれています。世界の注射用ヒアルロン酸＆ボツリヌス毒素市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、注射用ヒアルロン酸＆ボツリヌス毒素市場規模を推定する際に考慮しました。

・注射用ヒアルロン酸＆ボツリヌス毒素市場の概要
- 製品の定義
- 注射用ヒアルロン酸＆ボツリヌス毒素のタイプ別セグメント
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素市場規模：タイプ別分析（注射用ヒアルロン酸、ボツリヌス毒素）
- 注射用ヒアルロン酸＆ボツリヌス毒素の用途別セグメント
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素市場規模：用途別分析（化粧品、医療）
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素市場規模予測（2018年-2029年）
- 注射用ヒアルロン酸＆ボツリヌス毒素の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 注射用ヒアルロン酸＆ボツリヌス毒素市場の競争状況およびトレンド

・注射用ヒアルロン酸＆ボツリヌス毒素の地域別市場規模
- 北米の注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- アメリカの注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- ヨーロッパの注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- アジア太平洋の注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- 中国の注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- 日本の注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- 韓国の注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- インドの注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- オーストラリアの注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- 中南米の注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）
- 中東・アフリカの注射用ヒアルロン酸＆ボツリヌス毒素市場規模（2018年-2029年）

・タイプ別セグメント：注射用ヒアルロン酸、ボツリヌス毒素
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素のタイプ別販売量（2018年-2023年）
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素のタイプ別売上（2018年-2023年）
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素のタイプ別価格

・用途別セグメント：化粧品、医療
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素の用途別販売量（2018年-2023年）
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素の用途別売上（2018年-2023年）
- 世界の注射用ヒアルロン酸＆ボツリヌス毒素の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
AbbVie、Galderma、LG Life Sciences、Merz、Medytox、Hugel、Croma-Pharma、Beijing IMEIK、Bloomage Bio、Elravie (Humedix)、Cleviel (Pharma Research Products)、Haohai Biological、Teoxane、Sinclair、Suneva Medical、CG Bio、SciVision Biotech、Prollenium、Bohus BioTech、Caregen、Ipsen、LIBP、US World Meds、Daewoong、JETEMA

・産業チェーンと販売チャネルの分析
- 注射用ヒアルロン酸＆ボツリヌス毒素産業チェーン分析
- 注射用ヒアルロン酸＆ボツリヌス毒素の主要原材料
- 注射用ヒアルロン酸＆ボツリヌス毒素の販売チャネル
- 注射用ヒアルロン酸＆ボツリヌス毒素のディストリビューター
- 注射用ヒアルロン酸＆ボツリヌス毒素の主要顧客

・注射用ヒアルロン酸＆ボツリヌス毒素市場ダイナミクス
- 注射用ヒアルロン酸＆ボツリヌス毒素の業界動向
- 注射用ヒアルロン酸＆ボツリヌス毒素市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Dermal fillers can be very helpful in those with early signs of aging, or as a value-added part of facial rejuvenation surgery. Botulinum toxin (BTX) is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction and thus causes flaccid paralysis. Infection with the bacterium causes the disease botulism. The toxin is also used commercially in medicine, cosmetics and research.
Highlights
The global Injectable Hyaluronic Acid and Botulinum Toxin market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Injectable Hyaluronic Acid and Botulinum Toxin is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Injectable Hyaluronic Acid and Botulinum Toxin is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Injectable Hyaluronic Acid and Botulinum Toxin include AbbVie, Galderma, LG Life Sciences, Merz, Medytox, Hugel, Croma-Pharma, Beijing IMEIK and Bloomage Bio, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Injectable Hyaluronic Acid and Botulinum Toxin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Injectable Hyaluronic Acid and Botulinum Toxin.
The Injectable Hyaluronic Acid and Botulinum Toxin market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Injectable Hyaluronic Acid and Botulinum Toxin market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Injectable Hyaluronic Acid and Botulinum Toxin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
AbbVie
Galderma
LG Life Sciences
Merz
Medytox
Hugel
Croma-Pharma
Beijing IMEIK
Bloomage Bio
Elravie (Humedix)
Cleviel (Pharma Research Products)
Haohai Biological
Teoxane
Sinclair
Suneva Medical
CG Bio
SciVision Biotech
Prollenium
Bohus BioTech
Caregen
Ipsen
LIBP
US World Meds
Daewoong
JETEMA
Segment by Type
Injectable Hyaluronic Acid
Botulinum Toxin
Segment by Application
Cosmetic
Medical
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Injectable Hyaluronic Acid and Botulinum Toxin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Injectable Hyaluronic Acid and Botulinum Toxin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Injectable Hyaluronic Acid and Botulinum Toxin Market Overview
1.1 Product Overview and Scope of Injectable Hyaluronic Acid and Botulinum Toxin
1.2 Injectable Hyaluronic Acid and Botulinum Toxin Segment by Type
1.2.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Market Value Comparison by Type (2023-2029)
1.2.2 Injectable Hyaluronic Acid
1.2.3 Botulinum Toxin
1.3 Injectable Hyaluronic Acid and Botulinum Toxin Segment by Application
1.3.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Market Value by Application: (2023-2029)
1.3.2 Cosmetic
1.3.3 Medical
1.4 Global Injectable Hyaluronic Acid and Botulinum Toxin Market Size Estimates and Forecasts
1.4.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue 2018-2029
1.4.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales 2018-2029
1.4.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Injectable Hyaluronic Acid and Botulinum Toxin Market Competition by Manufacturers
2.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales Market Share by Manufacturers (2018-2023)
2.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Average Price by Manufacturers (2018-2023)
2.4 Global Injectable Hyaluronic Acid and Botulinum Toxin Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Injectable Hyaluronic Acid and Botulinum Toxin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Injectable Hyaluronic Acid and Botulinum Toxin, Product Type & Application
2.7 Injectable Hyaluronic Acid and Botulinum Toxin Market Competitive Situation and Trends
2.7.1 Injectable Hyaluronic Acid and Botulinum Toxin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Injectable Hyaluronic Acid and Botulinum Toxin Players Market Share by Revenue
2.7.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Injectable Hyaluronic Acid and Botulinum Toxin Retrospective Market Scenario by Region
3.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Region: 2018-2029
3.2.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Region: 2018-2023
3.2.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Region: 2024-2029
3.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Region: 2018-2029
3.3.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Region: 2018-2023
3.3.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Region: 2024-2029
3.4 North America Injectable Hyaluronic Acid and Botulinum Toxin Market Facts & Figures by Country
3.4.1 North America Injectable Hyaluronic Acid and Botulinum Toxin Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Injectable Hyaluronic Acid and Botulinum Toxin Sales by Country (2018-2029)
3.4.3 North America Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Injectable Hyaluronic Acid and Botulinum Toxin Market Facts & Figures by Country
3.5.1 Europe Injectable Hyaluronic Acid and Botulinum Toxin Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Injectable Hyaluronic Acid and Botulinum Toxin Sales by Country (2018-2029)
3.5.3 Europe Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Injectable Hyaluronic Acid and Botulinum Toxin Market Facts & Figures by Country
3.6.1 Asia Pacific Injectable Hyaluronic Acid and Botulinum Toxin Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Injectable Hyaluronic Acid and Botulinum Toxin Sales by Country (2018-2029)
3.6.3 Asia Pacific Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Injectable Hyaluronic Acid and Botulinum Toxin Market Facts & Figures by Country
3.7.1 Latin America Injectable Hyaluronic Acid and Botulinum Toxin Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Injectable Hyaluronic Acid and Botulinum Toxin Sales by Country (2018-2029)
3.7.3 Latin America Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Injectable Hyaluronic Acid and Botulinum Toxin Market Facts & Figures by Country
3.8.1 Middle East and Africa Injectable Hyaluronic Acid and Botulinum Toxin Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Injectable Hyaluronic Acid and Botulinum Toxin Sales by Country (2018-2029)
3.8.3 Middle East and Africa Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Type (2018-2029)
4.1.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Type (2018-2023)
4.1.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Type (2024-2029)
4.1.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales Market Share by Type (2018-2029)
4.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Type (2018-2029)
4.2.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Type (2018-2023)
4.2.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Type (2024-2029)
4.2.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue Market Share by Type (2018-2029)
4.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Price by Type (2018-2029)
5 Segment by Application
5.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Application (2018-2029)
5.1.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Application (2018-2023)
5.1.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales by Application (2024-2029)
5.1.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Sales Market Share by Application (2018-2029)
5.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Application (2018-2029)
5.2.1 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Application (2018-2023)
5.2.2 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue by Application (2024-2029)
5.2.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Revenue Market Share by Application (2018-2029)
5.3 Global Injectable Hyaluronic Acid and Botulinum Toxin Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AbbVie Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Galderma
6.2.1 Galderma Corporation Information
6.2.2 Galderma Description and Business Overview
6.2.3 Galderma Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Galderma Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.2.5 Galderma Recent Developments/Updates
6.3 LG Life Sciences
6.3.1 LG Life Sciences Corporation Information
6.3.2 LG Life Sciences Description and Business Overview
6.3.3 LG Life Sciences Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.3.4 LG Life Sciences Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.3.5 LG Life Sciences Recent Developments/Updates
6.4 Merz
6.4.1 Merz Corporation Information
6.4.2 Merz Description and Business Overview
6.4.3 Merz Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merz Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.4.5 Merz Recent Developments/Updates
6.5 Medytox
6.5.1 Medytox Corporation Information
6.5.2 Medytox Description and Business Overview
6.5.3 Medytox Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Medytox Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.5.5 Medytox Recent Developments/Updates
6.6 Hugel
6.6.1 Hugel Corporation Information
6.6.2 Hugel Description and Business Overview
6.6.3 Hugel Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Hugel Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.6.5 Hugel Recent Developments/Updates
6.7 Croma-Pharma
6.6.1 Croma-Pharma Corporation Information
6.6.2 Croma-Pharma Description and Business Overview
6.6.3 Croma-Pharma Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Croma-Pharma Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.7.5 Croma-Pharma Recent Developments/Updates
6.8 Beijing IMEIK
6.8.1 Beijing IMEIK Corporation Information
6.8.2 Beijing IMEIK Description and Business Overview
6.8.3 Beijing IMEIK Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Beijing IMEIK Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.8.5 Beijing IMEIK Recent Developments/Updates
6.9 Bloomage Bio
6.9.1 Bloomage Bio Corporation Information
6.9.2 Bloomage Bio Description and Business Overview
6.9.3 Bloomage Bio Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Bloomage Bio Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.9.5 Bloomage Bio Recent Developments/Updates
6.10 Elravie (Humedix)
6.10.1 Elravie (Humedix) Corporation Information
6.10.2 Elravie (Humedix) Description and Business Overview
6.10.3 Elravie (Humedix) Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Elravie (Humedix) Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.10.5 Elravie (Humedix) Recent Developments/Updates
6.11 Cleviel (Pharma Research Products)
6.11.1 Cleviel (Pharma Research Products) Corporation Information
6.11.2 Cleviel (Pharma Research Products) Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.11.3 Cleviel (Pharma Research Products) Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cleviel (Pharma Research Products) Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.11.5 Cleviel (Pharma Research Products) Recent Developments/Updates
6.12 Haohai Biological
6.12.1 Haohai Biological Corporation Information
6.12.2 Haohai Biological Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.12.3 Haohai Biological Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Haohai Biological Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.12.5 Haohai Biological Recent Developments/Updates
6.13 Teoxane
6.13.1 Teoxane Corporation Information
6.13.2 Teoxane Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.13.3 Teoxane Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Teoxane Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.13.5 Teoxane Recent Developments/Updates
6.14 Sinclair
6.14.1 Sinclair Corporation Information
6.14.2 Sinclair Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.14.3 Sinclair Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Sinclair Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.14.5 Sinclair Recent Developments/Updates
6.15 Suneva Medical
6.15.1 Suneva Medical Corporation Information
6.15.2 Suneva Medical Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.15.3 Suneva Medical Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Suneva Medical Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.15.5 Suneva Medical Recent Developments/Updates
6.16 CG Bio
6.16.1 CG Bio Corporation Information
6.16.2 CG Bio Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.16.3 CG Bio Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.16.4 CG Bio Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.16.5 CG Bio Recent Developments/Updates
6.17 SciVision Biotech
6.17.1 SciVision Biotech Corporation Information
6.17.2 SciVision Biotech Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.17.3 SciVision Biotech Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.17.4 SciVision Biotech Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.17.5 SciVision Biotech Recent Developments/Updates
6.18 Prollenium
6.18.1 Prollenium Corporation Information
6.18.2 Prollenium Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.18.3 Prollenium Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Prollenium Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.18.5 Prollenium Recent Developments/Updates
6.19 Bohus BioTech
6.19.1 Bohus BioTech Corporation Information
6.19.2 Bohus BioTech Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.19.3 Bohus BioTech Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Bohus BioTech Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.19.5 Bohus BioTech Recent Developments/Updates
6.20 Caregen
6.20.1 Caregen Corporation Information
6.20.2 Caregen Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.20.3 Caregen Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Caregen Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.20.5 Caregen Recent Developments/Updates
6.21 Ipsen
6.21.1 Ipsen Corporation Information
6.21.2 Ipsen Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.21.3 Ipsen Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Ipsen Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.21.5 Ipsen Recent Developments/Updates
6.22 LIBP
6.22.1 LIBP Corporation Information
6.22.2 LIBP Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.22.3 LIBP Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.22.4 LIBP Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.22.5 LIBP Recent Developments/Updates
6.23 US World Meds
6.23.1 US World Meds Corporation Information
6.23.2 US World Meds Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.23.3 US World Meds Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.23.4 US World Meds Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.23.5 US World Meds Recent Developments/Updates
6.24 Daewoong
6.24.1 Daewoong Corporation Information
6.24.2 Daewoong Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.24.3 Daewoong Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Daewoong Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.24.5 Daewoong Recent Developments/Updates
6.25 JETEMA
6.25.1 JETEMA Corporation Information
6.25.2 JETEMA Injectable Hyaluronic Acid and Botulinum Toxin Description and Business Overview
6.25.3 JETEMA Injectable Hyaluronic Acid and Botulinum Toxin Sales, Revenue and Gross Margin (2018-2023)
6.25.4 JETEMA Injectable Hyaluronic Acid and Botulinum Toxin Product Portfolio
6.25.5 JETEMA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Injectable Hyaluronic Acid and Botulinum Toxin Industry Chain Analysis
7.2 Injectable Hyaluronic Acid and Botulinum Toxin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Injectable Hyaluronic Acid and Botulinum Toxin Production Mode & Process
7.4 Injectable Hyaluronic Acid and Botulinum Toxin Sales and Marketing
7.4.1 Injectable Hyaluronic Acid and Botulinum Toxin Sales Channels
7.4.2 Injectable Hyaluronic Acid and Botulinum Toxin Distributors
7.5 Injectable Hyaluronic Acid and Botulinum Toxin Customers
8 Injectable Hyaluronic Acid and Botulinum Toxin Market Dynamics
8.1 Injectable Hyaluronic Acid and Botulinum Toxin Industry Trends
8.2 Injectable Hyaluronic Acid and Botulinum Toxin Market Drivers
8.3 Injectable Hyaluronic Acid and Botulinum Toxin Market Challenges
8.4 Injectable Hyaluronic Acid and Botulinum Toxin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 注射用ヒアルロン酸＆ボツリヌス毒素のグローバル市場2023年：注射用ヒアルロン酸、ボツリヌス毒素(Global Injectable Hyaluronic Acid and Botulinum Toxin Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ヒアルロン酸外科用癒着防止液のグローバル市場展望 2023年-2029年：ゲル、液体
  • ペットヒアルロン酸のグローバル市場予測2023-2029
  • ヒアルロン酸マイクロニードルパッチのグローバル市場2023年：唇用、目元用
  • 世界の注入用ヒアルロン酸市場インサイト及び予測（純度98％以下、純度98％以上）
  • 世界のタイプAボツリヌス毒素市場2022年：50U、100U、その他